← FDA DRUG APPROVALS

FDA ANDA · ANDA216608

ARIPIPRAZOLE

Sponsor: MYLAN

APPLICATION
ANDA216608
TYPE
ANDA
ORIGINAL APPROVAL
2024-12-03
LATEST ACTION
2024-12-03
ROUTE
INTRAMUSCULAR
DOSAGE FORM
FOR SUSPENSION, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

ARIPIPRAZOLEDiscontinued
ARIPIPRAZOLE 300MG/VIAL · FOR SUSPENSION, EXTENDED RELEASE · INTRAMUSCULAR
ARIPIPRAZOLEDiscontinued
ARIPIPRAZOLE 400MG/VIAL · FOR SUSPENSION, EXTENDED RELEASE · INTRAMUSCULAR

Approval history

2024-12-03UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →